NeuroSense Therapeutics Ltd.
August 01, 2025 - by Joey Ramson
$NRSN shares are sinking today despite highlighting progress in its ALS treatment development. They also announced that they are regaining Nasdaq compliance through a $5M private placement, advancing manufacturing capabilities to commercial scale, and preparing for a Phase 3 trial in H2 2025.
